GLENMARK

Adds further details and background throughout

Sept 24 (Reuters) - China's Jiangsu Hengrui Pharmaceuticals 600276.SS said on Wednesday it has agreed to grant a paid license for its innovative cancer drug trastuzumab rezetecan to the Swiss unit of India's Glenmark Pharmaceuticals GLEN.NS.

Under the agreement, Hengrui will receive an upfront payment of $18 million and can get milestone payments of up to $1.09 billion from Glenmark Specialty S.A. The Chinese firm will also be eligible for royalties on net sales of the drug in the licensed territories.

The deal gives the Indian company rights to a drug from a class called antibody drug conjugate. These drugs work like "guided missiles" by killing tumor cells while leaving healthy ones unharmed.

Their targeted approach has led to billions in investment from pharmaceutical giants such as US-based Merck MRK.N, Roche ROG.S and AstraZeneca AZN.L in recent years.

Hengrui's license gives the Glenmark unit exclusive rights to develop and commercialize the drug worldwide, excluding Mainland China, the Hong Kong and Macao SARs, Taiwan, the U.S., Europe and a few other regions, the Indian company said.

The drug was approved in China in May to treat an advanced form of non-small cell lung cancer after patients had tried at least one other treatment. Additional clinical studies on the drug are ongoing.

China's regulator is also reviewing the drug for several other forms of cancer.

The agreement will remain in force until the expiration of the royalty term for trastuzumab rezetecan, Hengrui said.

(Reporting by Shivangi Lahiri in Bengaluru; Editing by Leroy Leo)

(([email protected]))

** Shares of Glenmark Pharma GLEN.NS rise 2.8% to 2,047.3 rupees, their highest in over 3 weeks

** Drugmaker starts phase 3 trial of cancer drug Envafolimab in India after drug regulator's nod

** Company says clinical trial applications are underway in Russia, Brazil, and Mexico

** Stock rated "buy" on avg; median PT is 2,380 rupees - data compiled by LSEG

** Stock up 27.3% YTD

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

** Shares of Glenmark Pharmaceuticals GLEN.NS up 3.5% to 1985 rupees

** HSBC Global Investment Research retains "buy" rating and PT of 2,380 rupees ($27.20) on GLEN on the back of good visibility on growth drivers

** Easing R&D spend, start of supplies from Monroe plant, U.S. FDA approval for gFlovent, pick-up in the U.S. and India businesses led by new launches are key drivers for GLEN's growth - HSBC

** Stock set to rise most in a session since July 11

** Stock has been above its 100-day, 200-day simple moving avgs since June, indicating bullish sentiment

** Avg rating of nine analysts is "buy" and median PT is 2,380 rupees, ~19% higher than current price - data compiled by LSEG

** YTD, GLEN up ~24%

($1 = 87.5060 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Sept 2 (Reuters) - Glenmark Pharmaceuticals GLEN.NS:

• TO LAUNCH ERIBULIN MESYLATE INJECTION IN USA

• TO BEGIN DISTRIBUTION IN SEPTEMBER 2025

Source text: ID:nBSE5B7S0j

Further company coverage: GLEN.NS

(([email protected];))

Aug 19 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS INC TO LAUNCH MICAFUNGIN FOR INJECTION USP

Source text: ID:nnAZN4DSC95

Further company coverage: GLEN.NS

(([email protected];;))

** Shares of Glenmark Pharma GLEN.NS fall 1.45% to 2,014.9 rupees

** Drugmaker's Q1 consol PBT fell 9% to 4.19 bln rupees ($47.96 million), net sales down by 5% at 30.59 bln rupees hit by pricing pressure in North America and Europe

** Sales in North America slipped 0.4%, while that in Europe dropped 4% for the quarter

** Europe and Emerging markets businesses to deliver a double-digit growth from Q2 onwards, chairman says

** 9 analysts covering GLEN have a "buy" rating on average, median PT is 2,365 rupees - data compiled by LSEG

** Stock up ~25% YTD

($1 = 87.3675 Indian rupees)

(Reporting by Urvi Dugar)

(([email protected]))

Aug 14 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• APPROVES TRANSFER OF CONSUMER CARE BUSINESS TO SUBSIDIARY

• BUSINESS TRANSFER VALUED AT 2.40 BILLION RUPEES

Source text: ID:nBSE9HGC1t

Further company coverage: GLEN.NS

(([email protected];))

Adds analyst comment in paragraphs 6-7; updates shares

By Kashish Tandon

July 11 (Reuters) - Shares of India's Glenmark Pharmaceuticals GLEN.NS jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie ABBV.N for its early-stage blood cancer treatment.

The stock was the top percentage gainer on the Nifty Pharma index .NIPHARM, which traded 0.3% higher compared to a 0.8% loss in the benchmark Nifty 50 .NSEI.

AbbVie will get the exclusive rights to develop and commercialise ISB 2001 in North America, Europe, Japan and Greater China, according to the deal. Ichnos Glenmark Innovation (IGI) will receive an upfront payment of $700 million and could earn up to $1.22 billion in additional milestone payments.

"This is possibly the biggest deal by an Indian company in the biotechnology space," said Shrikant Akolkar, an analyst at brokerage Nuvama.

Nomura expects IGI to ramp up its research and development spending post the deal as "it is now well funded" and added that Glenmark could likely pursue an initial public offering for IGI in the near to medium term.

The deal validates the improved commercial prospects of innovative research and development, Motilal Oswal said. The brokerage raised its target price on the stock to 2,430 rupees from 1,690 rupees - the highest among nine analysts covering the stock, according to data compiled by LSEG.

Analysts, on average, rate the stock "buy", with the median price target at 1,665 rupees, well below current levels.

Glenmark is the best performer on the 20-member pharma index so far this year, gaining 30% versus a 4.8% decline in the sub-index.

(Additional reporting and writing by Hritam Mukherjee in Bengaluru; Editing by Sonia Cheema)

(([email protected]; X: @MukherjeeHritam;))

Corrects typo in company name to 'AbbVie' in headline

July 10 (Reuters) - India's Glenmark Pharmaceuticals GLEN.NS said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie ABBV.N have signed an exclusive licensing agreement for IGI's cancer treatment, adding to the U.S. firm's oncology portfolio.

Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize IGI's ISB 2001 in North America, Europe, Japan and Greater China.

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed or refractory multiple myeloma, a type of cancer that develops in white blood cells.

AbbVie has a pipeline of more than 20 investigational assets designed to tackle difficult-to-treat cancers, according to the company website.

Subject to regulatory approvals, IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in additional milestone payments, according to the agreement.

(Reporting by Chandini Monnappa, and Hritam Mukherjee, additional reporting by Ananta Agarwal in Bengaluru; Editing by Shreya Biswas)

(([email protected]; +918061822697;))

June 18 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• U.S. FDA INSPECTION AT THE COMPANY'S FACILITY AT MONROE, NORTH CAROLINA, USA

• COMPANY WAS ISSUED A FORM 483 WITH FIVE OBSERVATIONS BY USFDA

• OBSERVATIONS ARE PROCEDURAL IN NATURE

• THERE WAS NO OBSERVATION RELATED TO DATA INTEGRITY REPORTED

Source text: [ID:]

Further company coverage: GLEN.NS

(([email protected];;))

June 9 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• TO LAUNCH DCGI-APPROVED ZANUBRUTINIB IN INDIA

• ZANUBRUTINIB TO BE MARKETED AS BRUKINSA IN INDIA

Source text: ID:nBSE95v3F3

Further company coverage: GLEN.NS

(([email protected];;))

May 12 (Reuters) - Indian pharmaceutical stocks .NIPHARM shed 1.3% on Monday, even as the broader markets rose, after U.S. President Donald Trump said he would sign an executive order to cut prescription prices to the level paid by other high-income countries, an amount he put at 30% to 80% less.

Eight of the 20 stocks on the pharmaceutical sub-index were in the red, while the benchmark Nifty 50 index .NSEI was trading 2.4% higher.

Sun Pharma, India's top drugmaker by revenue, dropped 5.4% to be the top loser on the Nifty 50 and the pharma index. Glenmark Pharma GLEN.NS and Cipla CIPL.NS declined 0.4% and 1.5%, respectively.

Trump said he would sign the executive order on Monday morning to pursue what is known as "most favored nation" pricing or international reference pricing.

The U.S. pays the most in the world for many prescription drugs, often nearly triple that of other developed nations. Trump has said he wants to close that spread, but has not publicly specified how and did not provide details.

Several Indian drugmakers get a significant chunk of their revenue from North America by selling cheaper versions of the latest drugs.

The U.S. imports nearly a third of Indian pharma products sold overseas.

India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.

(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)

(([email protected]; 8800437922;))

May 5 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS LTD - IGI RECEIVES FDA FAST TRACK DESIGNATION FOR ISB 2001

Source text: ID:nBSE1SYXkx

Further company coverage: GLEN.NS

(([email protected];;))

April 29 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• CLAIRIFIES REPORT ABOUT CDSCO FLAGGING DRUGS

• PRODUCTS REFERRED TO IN REPORT SPURIOUS; NOT MADE BY CO

Source text: ID:nnAZN3RNEEN

Further company coverage: GLEN.NS

(([email protected];;))

April 16 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - GLENMARK PHARMACEUTICALS INC., USA TO LAUNCH DEXTROAMPHETAMINE SACCHARATE TABLETS

• GLENMARK PHARMA-GLENMARK PHARMA INC TO LAUNCH MIXED SALTS OF SINGLE ENTITY AMPHETAMINE PRODUCT TABLETS

Further company coverage: GLEN.NS

(([email protected];))

April 9 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 1.7% on Wednesday after U.S. President Donald Trump reiterated plans to announce a "major" tariff on all pharmaceutical imports.

U.S. accounts for a third of India's overall pharma exports.

Trump also threatened the duties on Friday, after his first set of reciprocal tariffs earlier last week exempted pharma products -- a change in stance that had prompted a wild swing in pharma stocks.

On the day, all twenty constituents of the pharma index were lower, with the index dragging down the benchmark Nifty 50 .NSEI by about 0.52% as of 9:20 a.m. IST.

Gland Pharma GLAD.NS, Lupin LUPN.NS and Zydus Lifesciences ZYDU.NS were the top losers by percentage, down between 3% and 5%.

Sun Pharma SUN.NS and Cipla CIPL.NS, the top constituents by weight, fell 1.69% and 1.87%, respectively.

India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. These currently attract almost no U.S. levies, while India imposes about 10% tax on U.S. pharma imports, according to industry experts.

The pharma index has fallen 14.4% this year.

(Reporting by Kashish Tandon and Ananta Agarwal in Bengaluru; Editing by Savio D'Souza)

(([email protected];))

April 1 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS INC., USA LAUNCHES VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 750 MG/VIAL, 1.25 G/VIAL AND 1.5 G/VIAL (SINGLE-DOSE VIAL)

Source text: ID:nPn4wYPFna

Further company coverage: GLEN.NS

(([email protected];))

March 27 - ** Shares of Glenmark Pharmaceuticals Ltd GLEN.NS rise 2.3% to 1,495.95 rupees
** Stock top gainer on Nifty Pharma .NIPHARM index, which is down 1%
** HSBC upgrades drugmaker to "buy" from "hold" citing visibility on margin expansion for its base business; raises PT to 1,785 rupees from 1,630 rupees
** Brokerage also sees scope for re-rating if GLEN secures a licensing deal for its targeted cancer therapy ISB 2001
** GLEN, like half the stocks on 20-member NIPHARM, is rated "buy" - data compiled by LSEG
** Stock trims YTD losses to ~7%, faring better than pharma stocks' nearly 10% drop this year

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

March 20 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS - RECEIVES FDA APPROVAL FOR OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION

Source text: ID:nBSE71jjXQ

Further company coverage: GLEN.NS

(([email protected];))

Feb 27 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS INC LAUNCHES EPINEPHRINE INJECTION USP MULTIPLE-DOSE VIAL

Source text: ID:nBSEtnRNn

Further company coverage: GLEN.NS

(([email protected];;))

** Shares of Glenmark Pharmaceuticals GLEN.NS up ~4% to 1350.5 rupees

** Co settles remaining antitrust and consumer protection lawsuits with three plaintiffs in connection with generic cholesterol drug Zetia

** Plaintiffs include Humana HUM.N, Centene Corp CNC.N

and Kaiser Foundation Health Plan [RIC:RIC:KISERF.UL]

** Under terms of $7 mln settlement, Glenmark denies allegations by plaintiffs, concedes no liability

** Including session's gains, GLEN shares up 48.3% in the last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

Feb 14 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA Q3 CONSOL NET PROFIT 3.48 BILLION RUPEES

• GLENMARK PHARMA Q3 CONSOL NET SALES 33.02 BILLION RUPEES

Source text: ID:nBSE5683hc

Further company coverage: GLEN.NS

(([email protected];))

Feb 10 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• RECEIVES MHRA APPROVAL TO MARKET WINLEVI IN UK

• WINLEVI APPROVED FOR TREATMENT OF ACNE VULGARIS IN PATIENTS AGED 12+

Source text: ID:nBSE85XZy7

Further company coverage: GLEN.NS

(([email protected];;))

Jan 21 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS - LAUNCHES PHYTONADIONE INJECTABLE EMULSION USP

Source text: ID:nNSEJjlCj

Further company coverage: GLEN.NS

(([email protected];;))

Dec 16 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS INC., USA LAUNCHES LACOSAMIDE ORAL SOLUTION, 10 MG/ML

Source text: ID:nBSE28f2Ds

Further company coverage: GLEN.NS

(([email protected];;))

Dec 10 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• IGI PRESENTS PHASE 1 DATA FOR ISB 2001 SHOWING HIGH ORR

• NO DOSE-LIMITING TOXICITIES OBSERVED IN ISB 2001 STUDY

Source text: ID:nNSEM8KQ0

Further company coverage: GLEN.NS

(([email protected];;))

Nov 27 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS INC., USA LAUNCHES TRAVOPROST OPHTHALMIC SOLUTION

Source text: [ID:]

Further company coverage: GLEN.NS

(([email protected];;))

Nov 14 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• Q2 CONSOL NET PROFIT 3.54 BILLION RUPEES

• Q2 CONSOL NET SALES 34 BILLION RUPEES

Source text: ID:nBSE4HFX6

Further company coverage: GLEN.NS

(([email protected];;))

** Shares of Glenmark Life Sciences GLEM.NS climb 3.5% at 971.20 rupees

** Brokerage Kotak Institutional Equities upgrades stock to "Buy" from "Reduce"

** GLEM's near-term outlook is intact as it continues to step up investments in capacity addition under Nirma, brokerage says

** Adds, new client wins in ts contract manufacturing segment, along with a rich API portfolio will be key growth drivers for the company in near term

** GLEM's stock fell 10% last week after downbeat Q2 results due to a temporary shutdown of its biggest manufacturing facility in Gujarat

** Analysts' avg rating on GLEM at "buy"; peers Laurus Labs LAUL.NS and Divi's Laboratories DIVI.NS rated "Hold" - LSEG data

** GLEM's ~48% YTD gain bigger than LAUL's ~15% climb but smaller than DIVI's ~49% rise

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))